TECHNOLOGY
TRANSFER PORTAL
Welcome to the Technology Transfer Portal. This space has been designed to promote technology transfer amongst ICGEB Member States to foster innovation in diagnostics, vaccines, therapeutics, new crops, biopesticides and biofuels. Explore the available portfolio of ICGEB technologies and contact us for more information.
technologies in development
Search By Organisation
| Product | Introduction | Sector/Discipline | Application Use | Developed By | Which ICGEB | Member State | Other Organization | Country |
|---|---|---|---|---|---|---|---|---|
| Use of MicroRNAs in the Treatment of Lung Diseases | Idiopathic pulmonary fibrosis (IPF) is a fibrotic lung disease causing chronic respiratory failure. In IPF, alveolar type II cells (ATIIs) are damaged and therefore cannot trans-differentiate to alveolar type I cells (ATIs), ATII to ATI trans-differentiation is an essential physiological process for effective alveolar repair after damage. Thus, ATII cells represent a relevant target for the development of new pro-regenerative therapies for the lung. We successfully identified microRNAs regulating ATII to ATI trans-differentiation. Specifically, our aim is to leverage these microRNAs to restore the natural regenerative capacity of human lungs, thereby mitigating the abnormal fibrotic response typically observed following chronic and acute alveolar damage. This therapeutic strategy holds potential not only for IPF but also for other lung diseases characterized by impaired lung repair mechanisms. | Biotherapy | Prevention/treatment of lung diseases. Read More | ICGEB | ICGEB Trieste, Italy | -1 | --NA-- | Italy |
| Human Alpha Galactosidase A Coding Sequence for the Treatment of Fabry Disease | Fabry disease is a rare lysosomal disorder, caused by mutations in the Alpha galactosidase (GLA) gene. Enzyme Replacement Therapy (ERT) and more recently, Chaperon Therapy products, have seen some success in the treatment of Fabry diseases. However, their high cost encourages the need for novel, more efficient and cheaper treatments. It has now been generated a codon optimized cDNA sequence expressing human GLA able to more efficiently produce in vivo the enzyme. | Gene Therapy | Treatment of Fabry Disease. Read More | ICGEB | ICGEB Trieste, Italy | -1 | --NA-- | Italy |
| Inhibitors of SARS-CoV-2 for the Prevention and Treatment of COVID-19 | 8-hydroxyquinoline cysteine protease inhibitors, and more specifically, nitroxoline and its derivatives, can be used in the prevention and/or treatment of COVID-19 caused by SARS-CoV-2. | Biotherapy | New treatment for SARS-CoV-2. Read More | ICGEB | ICGEB Trieste, Italy | -1 | --NA-- | Italy |
| End-Effector for Cell Volumetric Stimulation | Mechanobiology is a new field in the biological sciences aimed at studying the effects of mechanical stimulation on various cellular processes, such as metabolism, differentiation or proliferation. The present device and method of manufacturing the same is an end-effector for volumetric stimulation of cells, comprising an air-inflatable end-effector coupled to an actuator system. The device, which is designed for in vitro and ex vivo mechanobiology experiments, is compatible with most laboratory glassware or plastics, and is therefore compatible with medium- and high-processivity drug and biological molecule screening. | Biotherapy | In vitro mechanobiology experiments. Read More | ICGEB | ICGEB Trieste, Italy | -1 | --NA-- | Italy |
| AGENT FOR THE TREATMENT OF LEIOMYOMAS | The invention concerns anti-miRNA to be used for the treatment of uterine leiomyomas. In particular, the proposed innovation aims at developing a biologic drug able to reduce the size of the leiomyoma, not only its symptoms, without interfering with ovulation cycles and patient fertility. This would therefore reduce the necessity of surgical intervention. | Anti-Cancer | Possible Applications • New biologic drug able to reduce the size of leiomyomas (not only the symptoms). Read More | ICGEB | ICGEB Trieste, Italy | -1 | --NA-- | Italy |
| EMID2 - Biological Protein for Anti-Tumor and Anti-Metastasis Use | The invention describes a protein for the treatment of cancer and metastasis. It has been found that the administration of this protein has a strong impact on several aspects of the tumor microenvironment. Treatments able to act on the tumor microenvironment are highly desirable as they prevent cancer cell growth and invasiveness. | Anti-Cancer | : Possible Applications • Cancer treatment and prevention - colorectal cancer, breast cancer, lung cancer, epithelial cancers and melanoma; • Use in subjects with tumors that have not yet colonized distant organs; • Use in subjects with tumors that have already generated multiple metastases not amenable to surgical resection. Read More | ICGEB | ICGEB Trieste, Italy | -1 | --NA-- | Italy |